These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 38965822)

  • 1. Growth differentiation factor 15 is not modified after weight loss induced by liraglutide in South Asians and Europids with type 2 diabetes mellitus.
    Hoekx CA; Straat ME; Bizino MB; van Eyk HJ; Lamb HJ; Smit JWA; Jazet IM; de Jager SCA; Boon MR; Martinez-Tellez B
    Exp Physiol; 2024 Jul; ():. PubMed ID: 38965822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GDF15 acts synergistically with liraglutide but is not necessary for the weight loss induced by bariatric surgery in mice.
    Frikke-Schmidt H; Hultman K; Galaske JW; Jørgensen SB; Myers MG; Seeley RJ
    Mol Metab; 2019 Mar; 21():13-21. PubMed ID: 30685336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.
    Hemmingsen B; Sonne DP; Metzendorf MI; Richter B
    Cochrane Database Syst Rev; 2017 May; 5(5):CD012204. PubMed ID: 28489279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Weight Loss-Independent Effect of Liraglutide on Insulin Sensitivity in Individuals With Obesity and Prediabetes.
    Mashayekhi M; Nian H; Mayfield D; Devin JK; Gamboa JL; Yu C; Silver HJ; Niswender K; Luther JM; Brown NJ
    Diabetes; 2024 Jan; 73(1):38-50. PubMed ID: 37874653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial.
    Dejgaard TF; Frandsen CS; Hansen TS; Almdal T; Urhammer S; Pedersen-Bjergaard U; Jensen T; Jensen AK; Holst JJ; Tarnow L; Knop FK; Madsbad S; Andersen HU
    Lancet Diabetes Endocrinol; 2016 Mar; 4(3):221-232. PubMed ID: 26656289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucagon-Like Peptide-1 Receptor Agonist Utilization in Type 2 Diabetes in Japan: A Retrospective Database Analysis (JDDM 57).
    Ishigaki Y; Strizek A; Aranishi T; Arai N; Imaoka T; Cai Z; Maegawa H
    Diabetes Ther; 2021 Jan; 12(1):345-361. PubMed ID: 33300091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Near-normalization of glycaemic control with glucagon-like peptide-1 receptor agonist treatment combined with exercise in patients with type 2 diabetes.
    Mensberg P; Nyby S; Jørgensen PG; Storgaard H; Jensen MT; Sivertsen J; Holst JJ; Kiens B; Richter EA; Knop FK; Vilsbøll T
    Diabetes Obes Metab; 2017 Feb; 19(2):172-180. PubMed ID: 27717126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial.
    Pratley R; Amod A; Hoff ST; Kadowaki T; Lingvay I; Nauck M; Pedersen KB; Saugstrup T; Meier JJ;
    Lancet; 2019 Jul; 394(10192):39-50. PubMed ID: 31186120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A double-blind, placebo-controlled, randomised trial to assess the effect of liraglutide on ectopic fat accumulation in South Asian type 2 diabetes patients.
    van Eyk HJ; Paiman EHM; Bizino MB; de Heer P; Geelhoed-Duijvestijn PH; Kharagjitsingh AV; Smit JWA; Lamb HJ; Rensen PCN; Jazet IM
    Cardiovasc Diabetol; 2019 Jul; 18(1):87. PubMed ID: 31288820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differences in Inflammatory Pathways Between Dutch South Asians vs Dutch Europids With Type 2 Diabetes.
    Straat ME; Martinez-Tellez B; van Eyk HJ; Bizino MB; van Veen S; Vianello E; Stienstra R; Ottenhoff THM; Lamb HJ; Smit JWA; Jazet IM; Rensen PCN; Boon MR
    J Clin Endocrinol Metab; 2023 Mar; 108(4):931-940. PubMed ID: 36262060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and Efficacy of Liraglutide, 3.0 mg, Once Daily vs Placebo in Patients With Poor Weight Loss Following Metabolic Surgery: The BARI-OPTIMISE Randomized Clinical Trial.
    Mok J; Adeleke MO; Brown A; Magee CG; Firman C; Makahamadze C; Jassil FC; Marvasti P; Carnemolla A; Devalia K; Fakih N; Elkalaawy M; Pucci A; Jenkinson A; Adamo M; Omar RZ; Batterham RL; Makaronidis J
    JAMA Surg; 2023 Oct; 158(10):1003-1011. PubMed ID: 37494014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating total and intact GDF-15 levels are not altered in response to weight loss induced by liraglutide or lorcaserin treatment in humans with obesity.
    Valenzuela-Vallejo L; Chrysafi P; Bello-Ramos J; Bsata S; Mantzoros CS
    Metabolism; 2022 Aug; 133():155237. PubMed ID: 35700837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metformin and growth differentiation factor 15 (GDF15) in type 2 diabetes mellitus: A hidden treasure.
    Al-Kuraishy HM; Al-Gareeb AI; Alexiou A; Papadakis M; Nadwa EH; Albogami SM; Alorabi M; Saad HM; Batiha GE
    J Diabetes; 2022 Dec; 14(12):806-814. PubMed ID: 36444166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of liraglutide vs. lifestyle changes on soluble suppression of tumorigenesis-2 (sST2) and galectin-3 in obese subjects with prediabetes or type 2 diabetes after comparable weight loss.
    Simeone P; Tripaldi R; Michelsen A; Ueland T; Liani R; Ciotti S; Birkeland KI; Gulseth HL; Di Castelnuovo A; Cipollone F; Aukrust P; Consoli A; Halvorsen B; Santilli F
    Cardiovasc Diabetol; 2022 Mar; 21(1):36. PubMed ID: 35277168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials.
    Vilsbøll T; Christensen M; Junker AE; Knop FK; Gluud LL
    BMJ; 2012 Jan; 344():d7771. PubMed ID: 22236411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liraglutide and sitagliptin have no effect on intestinal microbiota composition: A 12-week randomized placebo-controlled trial in adults with type 2 diabetes.
    Smits MM; Fluitman KS; Herrema H; Davids M; Kramer MHH; Groen AK; Belzer C; de Vos WM; Cahen DL; Nieuwdorp M; van Raalte DH
    Diabetes Metab; 2021 Sep; 47(5):101223. PubMed ID: 33429063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liraglutide and not lifestyle intervention reduces soluble CD163 after comparable weight loss in obese participants with prediabetes or type 2 diabetes mellitus.
    Grannes H; Ueland T; Simeone P; Liani R; Guagnano MT; Aukrust P; Michelsen AE; Birkeland K; di Castelnuovo A; Cipollone F; Consoli A; Halvorsen B; Gregersen I; Santilli F
    Cardiovasc Diabetol; 2024 Apr; 23(1):146. PubMed ID: 38685051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fibroblast growth factor-21 is required for weight loss induced by the glucagon-like peptide-1 receptor agonist liraglutide in male mice fed high carbohydrate diets.
    Le TDV; Fathi P; Watters AB; Ellis BJ; Besing GK; Bozadjieva-Kramer N; Perez MB; Sullivan AI; Rose JP; Baggio LL; Koehler J; Brown JL; Bales MB; Nwaba KG; Campbell JE; Drucker DJ; Potthoff MJ; Seeley RJ; Ayala JE
    Mol Metab; 2023 Jun; 72():101718. PubMed ID: 37030441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
    Frias JP; Nauck MA; Van J; Kutner ME; Cui X; Benson C; Urva S; Gimeno RE; Milicevic Z; Robins D; Haupt A
    Lancet; 2018 Nov; 392(10160):2180-2193. PubMed ID: 30293770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation between baseline characteristics and clinical outcomes in a large population of diabetes patients treated with liraglutide in a real-world setting in Italy.
    Lapolla A; Frison V; Bettio M; Dal Pos M; Rocchini P; Panebianco G; Tadiotto F; Da Tos V; D'Ambrosio M; Marangoni A; Ferrari M; Pianta A; Balzano S; Confortin L; Lamonica M; Marin N; Strazzabosco M; Brun E; Mesturino CA; Simoncini M; Zen F; Bax G; Bonsembiante B; Cardone C; Dal Frà MG; Gallo A; Masin M; Piarulli F; Sartore G; Simioni N
    Clin Ther; 2015 Mar; 37(3):574-84. PubMed ID: 25626486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.